Sticking To Nitrosamine Evaluations Deadline Is Priority For EU Regulators

Industry's Request For A Standardized Approach Has Been Set Aside

EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.

Nitrosodimethylamine
Industry Wants A Standardized Process For Nitrosamine Risk Evaluations • Source: Shutterstock

EU drug regulators have turned down industry’s request for a standardized process to help sponsors identify products that are at risk of possible nitrosamine contamination within the six-month deadline ending on 26 March 2020.

Regulators have said that they do not have the time or the resources to develop or validate a standardized process...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography